- Home
- Product Candidates
- Burn Wound Infections
RECCE® 327 Topical
RECCE® 327 (R327) as a topical formulation is being studied for efficacy on a broad range of bacterial wounds, burns and skin infections.
Overview
Aggressive infection is the leading cause of death and morbidity of burn wound sufferers. The most relevant and dangerous of burn wound infections are those involving Staphylococcus aureus (S. aureus), a Gram-positive bacteria located on the skin and mucous membranes (most often the nasal area).
S. aureus is the most dangerous of all of the many common staphylococcal bacteria. This bacteria often causes skin infections; however, it can also cause pneumonia, bone infections, meningitis and other invasive infections.
With the emergence of multi-drug resistant strains such as Methicillin-resistant Staphylococcus aureus (MRSA or ‘golden staph’), effective treatment options are often lacking. Patients with MRSA have significantly longer hospital stays and are estimated to be 64% more likely to die than people with a non-resistant form of the infection.
Burn Wound Infection Cases and Fatalities by Geographical Area
Worldwide
11 million
cases requiring medical intervention annually
300,000
deaths annually
USA
500,000
burn wound injuries requiring medical intervention annually
Europe
710 million
European Burn Care market calculated at 530 million annually in 2020 expected to grow to 710 million by end of 2025
Australia
50,000
Approximately 50,000 burn-related hospital admissions annually
About RECCE® 327 Topical
RECCE® 327 (R327) as a topical formulation is being studied for efficacy on a broad range of bacterial wounds, burns and skin infections.
A preclinical topical burn study in rats showed significant antibacterial activity against MRSA: Data demonstrated reduced bacterial load and higher percentage of wound closure with increasing doses of R327 compared to Soframycin. A separate human skin model showed the R327 was non-irritating, even at high concentrations.
Helpful Sites
Fiona Wood Foundation
